ArticleFrontiers in pharmacology2025

Cost-effectiveness of iruplinalkib versus crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer patients in China.

Wanjie Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.